Laxmi Organic Industries has received a credit rating downgrade from CRISIL Ratings Limited, with the agency revising its long-term bank facilities rating to 'CRISIL AA-/Negative' from 'CRISIL AA/Negative'. The rating agency has simultaneously reaffirmed its 'CRISIL A1+' rating on the company's short-term bank facilities and commercial paper.

Rating Action Details

The rating revision affects Rs.1,170 crore of total bank loan facilities and Rs.150 crore of commercial paper. CRISIL's decision reflects concerns over the company's financial performance trajectory and medium-term outlook.

Financial Performance Decline

The downgrade stems from steeper than anticipated decline in revenue and profitability. Revenue from operations declined 9% to Rs.2,071 crore in the first nine months of fiscal 2026 from Rs.2,276 crore in the corresponding period of fiscal 2025. The decline was driven by significant challenges across both business segments.

The specialty chemical segment, contributing 27% of sales, experienced a sharp 22% revenue decline to Rs.566 crore. Meanwhile, the essential segment, representing 73% of sales, contracted 3% to Rs.1,505 crore. The specialty chemicals decline resulted from steep correction in realization of key products, phase out of a key high-margin agrochemical product, and deferment of deliveries of select products.

Margin Compression Across Segments

Operating margins deteriorated significantly to 4.4% in nine months of fiscal 2026 from 9.5% in the same period of fiscal 2025. The decline affected both key business segments, with specialty chemical margins contracting from 24% to 13%, while essential segment margins compressed from 3% to 1%.

Capital Investment and Future Outlook

The company is executing substantial capital expenditure of over Rs.700 crore in fiscal 2026, with approximately Rs.550 crore allocated to the Dahej plant and the balance towards the Lote plant and maintenance activities. By the nine-month period of fiscal 2026, Laxmi Organic had already incurred capex of over Rs.475 crore, funded through a mix of debt and internal accruals.

Despite current challenges, CRISIL expects revenue to potentially increase to Rs.3,300-3,500 crore over the medium term, driven by stable revenue from existing capacities and additional revenues from newly added capacities at Dahej and Lote facilities.

Financial Risk Profile Remains Stable

The company maintains a healthy capital structure with networth of Rs.1,928 crore as of September 30, 2025, against debt of Rs.330 crore, resulting in gearing of 0.17 times. However, adjusted interest coverage deteriorated to 6.00 times in the first nine months of fiscal 2026 from 18.68 times in the corresponding previous period due to declining profitability.

Market Position and Business Strengths

Laxmi Organic maintains strong market positions across its verticals, commanding approximately 34% market share in ethyl acetate and meeting close to 55% of domestic demand in diketene derivatives. The company serves over 620 customers across diverse end-user industries including pharmaceuticals, agrochemicals, dyes and pigments, with no single customer contributing more than 10% of revenue in fiscal 2025.

The negative outlook reflects sustained deterioration in operating margins and slower than expected recovery in operating efficiency and return on capital employed, while the financial risk profile is expected to remain comfortable over the medium term.

Laxmi Organic Industries Limited has released its unaudited financial results for the third quarter and nine months ended December 31, 2025, revealing a challenging operational environment with declining revenues and profitability metrics. The company also conducted an investor conference call on January 30, 2026, providing detailed insights into market conditions and strategic initiatives.

Financial Performance Overview

The company's standalone financial performance for Q3FY26 showed notable declines across key metrics compared to the previous year:

The consolidated results showed a similar trend, with revenue from operations declining to ₹7,186.82 million from ₹7,863.35 million in Q3FY25, representing an 8.6% decrease. EBITDA for the quarter stood at nearly ₹50 crores, down 33% compared to the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, the company's performance reflected sustained pressure:

Market Challenges and Business Segment Performance

During the earnings call, Managing Director and CEO Dr. Rajan Venkatesh highlighted that the global chemical industry continues to face challenges with ongoing cost optimization efforts, shutdowns, and supply chain restructuring. The company's Essentials business saw revenue decline by 6% while maintaining volumes, primarily due to acetic acid feedstock price impacts. The Specialties segment experienced a more significant 30% revenue decline attributed to price moderation (12%), absence of one-time campaign products from the previous year (5-6%), and the phaseout of agrochemical intermediates (10%).

Significant Operational Developments

The company implemented several important changes during the reporting period. A key development was the change in depreciation method from written down value to straight line method, resulting in lower depreciation expenses. Under the previous method, depreciation for Q3FY26 would have been higher by ₹288.97 million.

Additionally, Laxmi Organic reversed accrued liabilities of ₹407.27 million related to wheeling losses, wheeling charges, transmission losses and transmission charges levied by Maharashtra State Electricity Distribution Company Limited, based on a favorable order from MERC.

Project Updates and Strategic Initiatives

The Dahej facility represents the company's largest capex investment, with Phase 1 already online and Phase 2 focusing on diketene, ketene, and downstream derivatives expected to complete mechanical work by quarter-end. The company anticipates FY27 as the first year of qualification and ramp-up, with accelerated growth in FY28.

Corporate Governance and Regulatory Updates

The Board approved the re-appointment of Dr. Rajiv Banavali as an Independent Director for a second term from May 18, 2026, to May 17, 2028. The company exercised the option under Section 115BBA of the Income Tax Act to compute income tax at 25.17%, resulting in a deferred tax liability reversal of ₹97.18 million. Following new Labour Codes notification, the company recognized ₹38.02 million toward increased gratuity liability and compensated absences.

Market Outlook and Recovery Signals

Management noted early signs of improvement in key feedstock pricing, particularly acetic acid, which had declined over 20% in the past two years but recently rebounded from $320-330 levels to $360-380 range. The company expects ethyl acetate spreads to improve from the previous pain point of $90-100 to approximately $130 range. Demand signals from packaging, inks and adhesives remained stable, while agrochemicals showed moderate demand and pharmaceuticals remained stable.

Source: Earnings call transcript and financial results